Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | CASP7 | P55210 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25050103 | 0.89 | KMT2A (0.41) | KMT2ATDP1SLC6A2SLC6A3ALDH1A1 | |
| SCHEMBL21290242 | 0.88 | TDP1 (0.49) | KMT2ATDP1SLC6A2SLC6A3ALDH1A1 | |
| SCHEMBL24510712 | 0.86 | ALDH1A1 (0.47) | KMT2ATDP1SLC6A2SLC6A3ALDH1A1 | |
| SCHEMBL24490781 | 0.80 | MAPK1 (0.38) | KMT2AALDH1A1JAK2RAB9ANPC1 | |
| SCHEMBL13733547 | 0.79 | TDP1 (0.47) | KMT2ATDP1SLC6A2SLC6A3ALDH1A1 | |
| SCHEMBL23745082 | 0.77 | ALDH1A1 (0.46) | KMT2ATDP1SLC6A2SLC6A3ALDH1A1 | |
| SCHEMBL13735977 | 0.75 | KMT2A (0.43) | KMT2ATDP1SLC6A2SLC6A3ALDH1A1 | |
| SCHEMBL21559637 | 0.74 | TDP1 (0.45) | KMT2ATDP1SLC6A2SLC6A3ALDH1A1 | |
| SCHEMBL21923220 | 0.73 | TDP1 (0.44) | KMT2ATDP1SLC6A2SLC6A3ALDH1A1 | |
| SCHEMBL25694618 | 0.73 | RAB9A (0.50) | KMT2ATDP1SLC6A2SLC6A3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11759533-B2 | Methods and compositions for modulating gene expression | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2023-09-19 | — | — | US | disclosed |
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-09-14 | — | — | US | disclosed |
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-09-14 | — | — | US | disclosed |
| US-20230241077-A1 | COMPOUNDS AND METHODS FOR MODULATING FRATAXIN EXPRESSION | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2023-08-03 | — | — | US | disclosed |
| US-20230149550-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-05-18 | — | — | US | disclosed |
| US-20230149550-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-05-18 | — | — | US | disclosed |
| US-20230050819-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-02-16 | — | — | US | disclosed |
| US-20220177489-A1 | Next Generation Synthetic Transcription Factors | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2022-06-09 | — | — | US | disclosed |
| US-20210283265-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-09-16 | — | — | US | disclosed |
| US-20210284629-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-09-16 | — | — | US | disclosed |
| US-20210238226-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-08-05 | — | — | US | disclosed |
| US-20210228723-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-07-29 | — | — | US | disclosed |
| US-20200129522-A1 | COMPOUNDS AND METHODS FOR MODULATING FRATAXIN EXPRESSION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238226-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | ATXN2L, ATXN2, ATXN10 | KMT2A 2202/4885TDP1 201/4885SLC6A2 2532/4885 |
| US-20230149550-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | DMPK, DTYMK, MYCBP | KMT2A 1820/4885TDP1 70/4885SLC6A2 4105/4885 |
| US-20220177489-A1 | Next Generation Synthetic Transcription Factors | ZFX, RUNX1, JUN | KMT2A 930/4885TDP1 1692/4885SLC6A2 4301/4885 |
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, CBL, UBQLN2 | KMT2A 1091/4885TDP1 787/4885SLC6A2 925/4885 |
| US-20210283265-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, CBL, UBQLN2 | KMT2A 1091/4885TDP1 787/4885SLC6A2 925/4885 |
| US-20230050819-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | CYFIP2, TPX2, ATXN2 | KMT2A 851/4885TDP1 85/4885SLC6A2 941/4885 |
| US-20230241077-A1 | COMPOUNDS AND METHODS FOR MODULATING FRATAXIN EXPRESSION | BRD4, BICRA, BRDT | KMT2A 184/4885TDP1 1527/4885SLC6A2 4671/4885 |
| US-11759533-B2 | Methods and compositions for modulating gene expression | BRD4, BICRA, BRDT | KMT2A 63/4885TDP1 2132/4885SLC6A2 4510/4885 |
| US-20210228723-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | ZFX, F13B, GRN | KMT2A 1662/4885TDP1 268/4885SLC6A2 3986/4885 |
| US-20200129522-A1 | COMPOUNDS AND METHODS FOR MODULATING FRATAXIN EXPRESSION | BRD4, BICRA, BRDT | KMT2A 193/4885TDP1 1506/4885SLC6A2 4672/4885 |
| US-20210284629-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, UBQLN2, UBTF | KMT2A 1612/4885TDP1 585/4885SLC6A2 1806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.